BPC-157 for gut healing, TB-500 for tissue repair, or peptides for hair growth target mechanisms unrelated to metabolic hormone signaling
Limited data exists for: Understudied Populations: Adults over 75 years (increased sensitivity to appetite suppression) Adolescents (ongoing development considerations) Individuals with BMI under 27 (insufficient safety data) Pregnant or lactating individuals (no safety data) Individuals with significant psychiatric conditions Gender Considerations: Research suggests some metabolic peptides may show differential effects between males and females, though data for cagrilintide and retatrutide specifically remains limited
For now, any GLP-1 patch being sold is not a legitimate, tested, or safe pharmaceutical product
What This Means for Our Practice Seven additional Phase 3 trials are expected in 2026, evaluating retatrutide across obesity, type 2 diabetes, sleep apnea, chronic low back pain, and MASLD
Cost asks what the full expense would be through that pathway
Every lot is independently tested for identity, purity, and content, with a lot-specific Certificate of Analysis available for review
